We are analyzing https://link.springer.com/article/10.1007/s12672-018-0343-8.

Title:
Insulin Receptor Substrate Suppression by the Tyrphostin NT157 Inhibits Responses to Insulin-Like Growth Factor-I and Insulin in Breast Cancer Cells | Discover Oncology
Description:
Insulin and insulin-like growth factor (IGF) signaling systems regulate breast cancer growth, progression, and metastasis. The insulin receptor substrates 1 and 2 (IRS1/2) transduce signaling from the type I IGF receptor (IGF-IR) and insulin receptor (InR) to mediate the biological effects of receptor activation. In breast cancer, IRS-1 plays a critical role in cancer cell proliferation while IRS-2 is associated with motility and metastasis. NT157, a small-molecule tyrphostin, downregulates IRS proteins in several model systems. In breast cancer cells, NT157 treatment suppressed IRS protein expression in a dose-dependent manner. Exposure to NT157 inhibited the activation of downstream signaling mediated by the IRS proteins. NT157 induced a MAPK-dependent serine phosphorylation of IRS proteins which resulted in disassociation between IRS proteins and their receptors resulting in IRS degradation. In estrogen receptor-α-positive (ERα+) breast cancer cells (MCF-7 and T47D), NT157 also resulted in cytoplasmic ERα downregulation likely because of disruption of an IRS-1-IGF-IR/InR/ERα complex. NT157 decreased S phase fraction, monolayer, and anchorage-independent growth after IGF/insulin treatment in ERα+ breast cancer cells. NT157 downregulation of IRS protein expression also sensitized ERα+ breast cancer cells to rapamycin. Moreover, NT157 inhibited the growth of tamoxifen-resistant ERα+ breast cancer cells. Given that both IGF-IR and InR play a role in cancer biology, targeting of IRS adaptor proteins may be a more effective strategy to inhibit the function of these receptors.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Science
Health & Fitness
Education

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

The income method remains a mystery to us.

Websites don't always need to be profitable; some serve as platforms for education or personal expression. Websites can serve multiple purposes. And this might be one of them. Link.springer.com might be earning cash quietly, but we haven't detected the monetization method.

Keywords {🔍}

irs, cancer, cells, breast, erα, growth, cell, protein, signaling, mcf, fig, receptor, expression, proteins, data, article, insulin, overnight, treatment, levels, google, scholar, igfi, cas, treated, determined, induced, degradation, lines, cyclin, yee, results, immunoblotting, total, sirna, starved, insulinlike, igfir, effects, proliferation, actin, panels, serumstarved, panel, serine, phosphorylation, resulted, downregulation, monolayer, tamr,

Topics {✒️}

horseradish peroxidase-conjugated anti-phosphotyrosine disrupt igf-ir/ir-irs-1-erα complex irs-1-igf-ir/inr complex resulting endocrine-resistant breast cancer irs-1-igf-ir/inr/erα complex hormone-resistant tamr cancers mcf-7l tamoxifen-resistant independent triplicates experiments estrogen receptor-α-positive anti-igf-ir-targeted therapies igf-i-stimulated cyclin d1 viola-villegas nt igf-ir monoclonal antibody erα-negative breast cancers irs-igf-ir/inr complex er-positive breast cancers anchorage-independent growth assays ligand-induced erα phosphorylation affect short-term igf transit-siquest transfection reagent masonic cancer center erα + breast cancer cells treatment-induced signaling transduction jie ying chan estrogen receptor alpha insulin receptor substrate insulin receptor substrate-1 insulin receptor substrate-2 nt157 inhibited igf-ir mapk-dependent serine phosphorylation growth factor-mediated signaling small-molecule tyrphostin targeting obesity-induced insulin resistance mediate igf/insulin signaling estrogen-depleted growth media estrogen receptor-positive propidium iodide-stained nuclei igf-i-treated conditions targeting igf-ir axis insulin receptor substrates erα-regulated gene expression erα+ cell lines human breast cancer dose-response curves showed related subjects igf-ir/ir required phospho-igf-ir/ir nt157 binds igf-1r irs-1-igf-ir/ir douglas yee

Questions {❓}

Yee D (2012) Insulin-like growth factor receptor inhibitors: baby or the bathwater?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Insulin Receptor Substrate Suppression by the Tyrphostin NT157 Inhibits Responses to Insulin-Like Growth Factor-I and Insulin in Breast Cancer Cells
         description:Insulin and insulin-like growth factor (IGF) signaling systems regulate breast cancer growth, progression, and metastasis. The insulin receptor substrates 1 and 2 (IRS1/2) transduce signaling from the type I IGF receptor (IGF-IR) and insulin receptor (InR) to mediate the biological effects of receptor activation. In breast cancer, IRS-1 plays a critical role in cancer cell proliferation while IRS-2 is associated with motility and metastasis. NT157, a small-molecule tyrphostin, downregulates IRS proteins in several model systems. In breast cancer cells, NT157 treatment suppressed IRS protein expression in a dose-dependent manner. Exposure to NT157 inhibited the activation of downstream signaling mediated by the IRS proteins. NT157 induced a MAPK-dependent serine phosphorylation of IRS proteins which resulted in disassociation between IRS proteins and their receptors resulting in IRS degradation. In estrogen receptor-α-positive (ERα+) breast cancer cells (MCF-7 and T47D), NT157 also resulted in cytoplasmic ERα downregulation likely because of disruption of an IRS-1-IGF-IR/InR/ERα complex. NT157 decreased S phase fraction, monolayer, and anchorage-independent growth after IGF/insulin treatment in ERα+ breast cancer cells. NT157 downregulation of IRS protein expression also sensitized ERα+ breast cancer cells to rapamycin. Moreover, NT157 inhibited the growth of tamoxifen-resistant ERα+ breast cancer cells. Given that both IGF-IR and InR play a role in cancer biology, targeting of IRS adaptor proteins may be a more effective strategy to inhibit the function of these receptors.
         datePublished:2018-09-18T00:00:00Z
         dateModified:2018-09-18T00:00:00Z
         pageStart:371
         pageEnd:382
         sameAs:https://doi.org/10.1007/s12672-018-0343-8
         keywords:
            Inhibits Insulin Receptor Substrate-1
            Nt Treatment
            Serine Phosphorylation
            Anaplastic Lymphoma Receptor Tyrosine Kinase
            Multiple Breast Cancer Cell Lines
            Oncology
            Cancer Research
            Surgical Oncology
            Molecular Medicine
            Radiotherapy
            Internal Medicine
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12672-018-0343-8/MediaObjects/12672_2018_343_Fig1_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12672-018-0343-8/MediaObjects/12672_2018_343_Fig2_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12672-018-0343-8/MediaObjects/12672_2018_343_Fig3_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12672-018-0343-8/MediaObjects/12672_2018_343_Fig4_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12672-018-0343-8/MediaObjects/12672_2018_343_Fig5_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12672-018-0343-8/MediaObjects/12672_2018_343_Fig6_HTML.png
         isPartOf:
            name:Hormones and Cancer
            issn:
               1868-8500
               1868-8497
            volumeNumber:9
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer US
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Yuzhe Yang
               affiliation:
                     name:University of Minnesota
                     address:
                        name:Department of Pharmacology, University of Minnesota, Minneapolis, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Jie Ying Chan
               affiliation:
                     name:University of Minnesota
                     address:
                        name:Department of Pharmacology, University of Minnesota, Minneapolis, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Nuri A. Temiz
               affiliation:
                     name:University of Minnesota
                     address:
                        name:Masonic Cancer Center, University of Minnesota, Minneapolis, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Douglas Yee
               url:http://orcid.org/0000-0002-3387-4009
               affiliation:
                     name:University of Minnesota
                     address:
                        name:Department of Pharmacology, University of Minnesota, Minneapolis, USA
                        type:PostalAddress
                     type:Organization
                     name:University of Minnesota
                     address:
                        name:Masonic Cancer Center, University of Minnesota, Minneapolis, USA
                        type:PostalAddress
                     type:Organization
                     name:University of Minnesota
                     address:
                        name:Department of Medicine, University of Minnesota, Minneapolis, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Insulin Receptor Substrate Suppression by the Tyrphostin NT157 Inhibits Responses to Insulin-Like Growth Factor-I and Insulin in Breast Cancer Cells
      description:Insulin and insulin-like growth factor (IGF) signaling systems regulate breast cancer growth, progression, and metastasis. The insulin receptor substrates 1 and 2 (IRS1/2) transduce signaling from the type I IGF receptor (IGF-IR) and insulin receptor (InR) to mediate the biological effects of receptor activation. In breast cancer, IRS-1 plays a critical role in cancer cell proliferation while IRS-2 is associated with motility and metastasis. NT157, a small-molecule tyrphostin, downregulates IRS proteins in several model systems. In breast cancer cells, NT157 treatment suppressed IRS protein expression in a dose-dependent manner. Exposure to NT157 inhibited the activation of downstream signaling mediated by the IRS proteins. NT157 induced a MAPK-dependent serine phosphorylation of IRS proteins which resulted in disassociation between IRS proteins and their receptors resulting in IRS degradation. In estrogen receptor-α-positive (ERα+) breast cancer cells (MCF-7 and T47D), NT157 also resulted in cytoplasmic ERα downregulation likely because of disruption of an IRS-1-IGF-IR/InR/ERα complex. NT157 decreased S phase fraction, monolayer, and anchorage-independent growth after IGF/insulin treatment in ERα+ breast cancer cells. NT157 downregulation of IRS protein expression also sensitized ERα+ breast cancer cells to rapamycin. Moreover, NT157 inhibited the growth of tamoxifen-resistant ERα+ breast cancer cells. Given that both IGF-IR and InR play a role in cancer biology, targeting of IRS adaptor proteins may be a more effective strategy to inhibit the function of these receptors.
      datePublished:2018-09-18T00:00:00Z
      dateModified:2018-09-18T00:00:00Z
      pageStart:371
      pageEnd:382
      sameAs:https://doi.org/10.1007/s12672-018-0343-8
      keywords:
         Inhibits Insulin Receptor Substrate-1
         Nt Treatment
         Serine Phosphorylation
         Anaplastic Lymphoma Receptor Tyrosine Kinase
         Multiple Breast Cancer Cell Lines
         Oncology
         Cancer Research
         Surgical Oncology
         Molecular Medicine
         Radiotherapy
         Internal Medicine
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12672-018-0343-8/MediaObjects/12672_2018_343_Fig1_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12672-018-0343-8/MediaObjects/12672_2018_343_Fig2_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12672-018-0343-8/MediaObjects/12672_2018_343_Fig3_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12672-018-0343-8/MediaObjects/12672_2018_343_Fig4_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12672-018-0343-8/MediaObjects/12672_2018_343_Fig5_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12672-018-0343-8/MediaObjects/12672_2018_343_Fig6_HTML.png
      isPartOf:
         name:Hormones and Cancer
         issn:
            1868-8500
            1868-8497
         volumeNumber:9
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer US
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Yuzhe Yang
            affiliation:
                  name:University of Minnesota
                  address:
                     name:Department of Pharmacology, University of Minnesota, Minneapolis, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Jie Ying Chan
            affiliation:
                  name:University of Minnesota
                  address:
                     name:Department of Pharmacology, University of Minnesota, Minneapolis, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Nuri A. Temiz
            affiliation:
                  name:University of Minnesota
                  address:
                     name:Masonic Cancer Center, University of Minnesota, Minneapolis, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Douglas Yee
            url:http://orcid.org/0000-0002-3387-4009
            affiliation:
                  name:University of Minnesota
                  address:
                     name:Department of Pharmacology, University of Minnesota, Minneapolis, USA
                     type:PostalAddress
                  type:Organization
                  name:University of Minnesota
                  address:
                     name:Masonic Cancer Center, University of Minnesota, Minneapolis, USA
                     type:PostalAddress
                  type:Organization
                  name:University of Minnesota
                  address:
                     name:Department of Medicine, University of Minnesota, Minneapolis, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Hormones and Cancer
      issn:
         1868-8500
         1868-8497
      volumeNumber:9
Organization:
      name:Springer US
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:University of Minnesota
      address:
         name:Department of Pharmacology, University of Minnesota, Minneapolis, USA
         type:PostalAddress
      name:University of Minnesota
      address:
         name:Department of Pharmacology, University of Minnesota, Minneapolis, USA
         type:PostalAddress
      name:University of Minnesota
      address:
         name:Masonic Cancer Center, University of Minnesota, Minneapolis, USA
         type:PostalAddress
      name:University of Minnesota
      address:
         name:Department of Pharmacology, University of Minnesota, Minneapolis, USA
         type:PostalAddress
      name:University of Minnesota
      address:
         name:Masonic Cancer Center, University of Minnesota, Minneapolis, USA
         type:PostalAddress
      name:University of Minnesota
      address:
         name:Department of Medicine, University of Minnesota, Minneapolis, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Yuzhe Yang
      affiliation:
            name:University of Minnesota
            address:
               name:Department of Pharmacology, University of Minnesota, Minneapolis, USA
               type:PostalAddress
            type:Organization
      name:Jie Ying Chan
      affiliation:
            name:University of Minnesota
            address:
               name:Department of Pharmacology, University of Minnesota, Minneapolis, USA
               type:PostalAddress
            type:Organization
      name:Nuri A. Temiz
      affiliation:
            name:University of Minnesota
            address:
               name:Masonic Cancer Center, University of Minnesota, Minneapolis, USA
               type:PostalAddress
            type:Organization
      name:Douglas Yee
      url:http://orcid.org/0000-0002-3387-4009
      affiliation:
            name:University of Minnesota
            address:
               name:Department of Pharmacology, University of Minnesota, Minneapolis, USA
               type:PostalAddress
            type:Organization
            name:University of Minnesota
            address:
               name:Masonic Cancer Center, University of Minnesota, Minneapolis, USA
               type:PostalAddress
            type:Organization
            name:University of Minnesota
            address:
               name:Department of Medicine, University of Minnesota, Minneapolis, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Department of Pharmacology, University of Minnesota, Minneapolis, USA
      name:Department of Pharmacology, University of Minnesota, Minneapolis, USA
      name:Masonic Cancer Center, University of Minnesota, Minneapolis, USA
      name:Department of Pharmacology, University of Minnesota, Minneapolis, USA
      name:Masonic Cancer Center, University of Minnesota, Minneapolis, USA
      name:Department of Medicine, University of Minnesota, Minneapolis, USA

External Links {🔗}(89)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

5.06s.

LINK . SPRINGER . COM {}